Nature Communications (Mar 2025)

Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial

  • Hui-Sheng Chen,
  • Zi-Ai Zhao,
  • Xin-Yu Shen,
  • Si-Qi Qiu,
  • Yu Cui,
  • Jing Qiu,
  • Wei Li,
  • Hong Zhang,
  • Wen-Huo Chen,
  • Li-Hua Wang,
  • De-Hui Zhang,
  • Ying Chen,
  • Yu-Tong Ma,
  • Zong-En Gao,
  • Shou-Chun Wang,
  • Di Li,
  • Hua Liu,
  • Thanh N. Nguyen

DOI
https://doi.org/10.1038/s41467-025-57774-x
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 8

Abstract

Read online

Abstract This phase II, randomized, double blinded, multi-center study aims to explore whether intravenous edaravone dexborneol (ED) could improve clinical outcomes in patients with anterior circulation stroke with successful endovascular reperfusion (ClinicalTrials.gov: NCT04667637). Eligible patients were randomly (1:1) assigned into ED, which received intravenous ED (37.5 mg, 2/day, for 12 days) or control group, which received placebo. The primary endpoint was favorable functional outcome (a modified Rankin Scale [mRS] of 0–2 at 90 days). Two hundred patients were enrolled, including 97 in ED group and 103 in control group. The proportion of patients with 90-day mRS (0–2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion.